Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial

Market-Moving Exclusives

EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases
EXCLUSIVE: Curanex Pipeline Expansion Signals Push Beyond Inflammation, Metabolic Diseases
EXCLUSIVE: FibroBiologics Moves Forward With Human Trial For Diabetic Foot Ulcer Therapy
EXCLUSIVE: FibroBiologics Moves Forward With Human Trial For Diabetic Foot Ulcer Therapy
EXCLUSIVE: Avalon Teams Up With AWS Partner To Build Automated Video Platform
EXCLUSIVE: Avalon Teams Up With AWS Partner To Build Automated Video Platform
EXCLUSIVE: FibroBiologics Moves Forward With Human Trial For Diabetic Foot Ulcer Therapy
EXCLUSIVE: FibroBiologics Moves Forward With Human Trial For Diabetic Foot Ulcer Therapy
EXCLUSIVE: Avalon Teams Up With AWS Partner To Build Automated Video Platform
EXCLUSIVE: Avalon Teams Up With AWS Partner To Build Automated Video Platform
EXCLUSIVE: ZenaTech Unveils 'IQ Aqua' Underwater Drone To Fight Undersea Mines
EXCLUSIVE: ZenaTech Unveils 'IQ Aqua' Underwater Drone To Fight Undersea Mines
EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch
EXCLUSIVE: Penny Stock Kala Bio Transitions To Revenue Model With AI Platform Launch

Market-Moving Exclusives Recent News

EXCLUSIVE: Hoth Therapeutics Targets Faster Drug Discovery With New AI Platform
EXCLUSIVE: Hoth Therapeutics Targets Faster Drug Discovery With New AI Platform
Hoth Therapeutics launches OpenClaw AI platform to speed drug discovery, improve data integration, and boost development efficiency.
Mark Zuckerberg's Meta Platforms $9 Trillion AI Moonshot Could Unlock Massive Executive Paydays If The Bet Pays Off
Mark Zuckerberg's Meta Platforms $9 Trillion AI Moonshot Could Unlock Massive Executive Paydays If The Bet Pays Off
Meta Platforms unveils executive stock plan tied to $9 trillion valuation by 2031, signaling aggressive growth targets and high-stakes incentives.
EXCLUSIVE: Co-Diagnostics Ships Diagnostic Tests To India Ahead Of TB Study Launch
EXCLUSIVE: Co-Diagnostics Ships Diagnostic Tests To India Ahead Of TB Study Launch
Co-Diagnostics ships PCR Pro and TB test kits to India, advancing clinical studies as the WHO backs NPOC diagnostics.
EXCLUSIVE: ZenaTech To Build $5,000 'Drone Hunter' To Shield From AI Swarm Attacks
EXCLUSIVE: ZenaTech To Build $5,000 'Drone Hunter' To Shield From AI Swarm Attacks
ZenaTech (ZENA) is launching an AI-driven counter-drone system to stop low-cost aerial threats. Discover how a single operator can control a fleet of interceptors to neutralize hostile drones at machine speed.
EXCLUSIVE: Co-Diagnostics Expands South Asia Reach, Targets $13 Billion Market Opportunity
EXCLUSIVE: Co-Diagnostics Expands South Asia Reach, Targets $13 Billion Market Opportunity
Co-Diagnostics expands CoSara's reach across South Asia, targeting a $13 billion market and boosting access to rapid diagnostic solutions.
EXCLUSIVE: Aduro Moves Closer To Commercializing Its Recycling Tech
EXCLUSIVE: Aduro Moves Closer To Commercializing Its Recycling Tech
Aduro signs agreement to scale its plastic recycling technology through global partnership and licensing strategy.
EXCLUSIVE: Beeline Rolls Out 24/7 Self-Service Mortgage Platform For Instant Loan Options
EXCLUSIVE: Beeline Rolls Out 24/7 Self-Service Mortgage Platform For Instant Loan Options
Beeline launches AI-powered digital mortgage tool letting borrowers review loans and lock rates online. BLNE stock rises in premarket.
EXCLUSIVE: ZenaTech Files New Patent For Drone Interceptor System
EXCLUSIVE: ZenaTech Files New Patent For Drone Interceptor System
ZenaTech (ZENA) shares rose after filing a patent for its "ZenaDrone 2000" and "IQ Glider." See how this autonomous launch and refueling system aims to neutralize low-cost drone threats at sea.
EXCLUSIVE: Beeline Launches Tokenized Home Equity Initiative With TYTL Partnership
EXCLUSIVE: Beeline Launches Tokenized Home Equity Initiative With TYTL Partnership
Beeline partners with TYTL to launch tokenized home equity platform, unlocking liquidity from homeowner assets.
Healthcare Startup Andel Says Its Employer GLP-1 Model Bypasses PBMs, May Lower Costs For Eli Lilly's Zepbound
Healthcare Startup Andel Says Its Employer GLP-1 Model Bypasses PBMs, May Lower Costs For Eli Lilly's Zepbound
Andel launches a PBM-free employer platform offering Eli Lilly and Company's (NYSE: LLY) Zepbound KwikPen at lower cash prices. CEO Jay Bregman tells Benzinga how the model works and why PBMs can't copy it.
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved